PMID: 9635917Jun 23, 1998Paper

Expanding the options for risk-based therapy in febrile neutropenia

Diagnostic Microbiology and Infectious Disease
K V Rolston

Abstract

Fever in neutropenic cancer patients is often due to the development of an infection. The standard management of febrile neutropenic patients involves the administration of empiric, hospital-based, parenteral antibiotic therapy. Although this treatment strategy has evolved from experience in high-risk patients with hematological malignancies, in whom bacterial infection can result in substantial morbidity and mortality, it has been adopted for all patients with febrile neutropenia, largely because of the inability of clinicians to reliably distinguish between patients who are at high risk for developing such morbidity/mortality and those who are not. The development of risk-assessment models has facilitated the recognition of high-, moderate-, and low-risk subgroups among febrile neutropenic patients and allows the administration of outpatient antibiotic therapy to the moderate- and low-risk groups, with the same degree of efficacy and safety as hospital-based therapy. Monotherapy with the carbapenems (imipenem/cilastatin and meropenem), with their broad spectrum of activity and established efficacy in high-risk patients, represents realistic options for risk-based treatment of febrile neutropenic patients within and outside th...Continue Reading

References

Nov 1, 1993·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·B S Koll, A E Brown
Jan 1, 1996·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·F Rossini
Jun 1, 1996·Infectious Disease Clinics of North America·K V RolstonA Freifeld
Oct 6, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W T HughesL S Young

❮ Previous
Next ❯

Citations

Aug 26, 1999·Seminars in Oncology Nursing·B K Shelton
Apr 30, 1999·International Journal of Antimicrobial Agents·J S BradleyJ P Quinn
Jan 30, 2004·Annual Review of Medicine·Kenneth V I Rolston
Jun 25, 2009·Seminars in Hematology·Jessica M ValdezThomas J Walsh
Jul 13, 2001·Infectious Disease Clinics of North America·H Giamarellou, A Antoniadou
Oct 9, 1998·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·K V Rolston
Jul 2, 2003·Cancer·Harrys A TorresDimitrios P Kontoyiannis
Aug 28, 2002·The Annals of Pharmacotherapy·Wendelin K NelsonRoger H Giller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.